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The generation of antigen-specific CTL is regulated by antigen and soluble
growth factors. The lymphokine IL-2 is considered to play a central role in the
process of CTL formation and has been shown to induce both long-term
proliferation of CTL (1) and differentiation of CTL precursors to the cytolytic
state (2). However, the involvement ofadditional soluble CTL regulatory factors
has been postulated (3-8). Using a murine MLC model system, we recently
demonstrated that the lymphokine B cell stimulatory factor 1 (9) (BSF-1 i or IL-
4) is, like IL-2, an extremely potent helper factor for the generation of alloreac-
tive CTL (10). Under the conditions used in that study, IL-2 was distinguished
from BSF-1 by its ability to induce a lytic population from unprimed precursors
in the absence of an overt antigenic stimulus (10). Cytolytic cells generated in
this manner have been observed previously in both mouse and man and have
been referred to as lymphokine-activated killer, or LAK, cells (11-13). Such
populations have a poorly defined target specificity and will lyse a wide array of
tumor target cells (12) and, in some cases, normal lymphocytes (14).
In the experiments reported here we examined the regulation of human CTL
and LAK cells by IL-2 and BSF-1 . We observed that CTL generation in human
MLC is augmented by BSF-1, provided it is added to cultures after an initial
period of activation. However, in spite of its ability to enhance antigen-specific
CTL development, BSF-1 had virtually no detectable LAK-inducing activity. In
both the CTL and LAK systems, BSF-1 inhibited the development of effector
cells that normally occurs in response to IL-2 when it was present together with
IL-2 at the beginning of culture. These results may have important implications
for immunotherapeutic strategies involving these lymphokines or cells grown in
their presence.
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Materials and Methods
Cells.
￿
PBMC were isolated by centrifugation over Isolymph (density = 1 .077 g/cm';
Gallard-Schlesinger Chemical Mfg. Corp., Carle Place, NY). A portion of the cell suspen-
sions to be used as stimulating cells was irradiated (3,000 rad) using a 1s1CS source. The
M. B. Widmer is aScholarof the Leukemia Society of America.
' Abbreviations used in this paper:
￿
BSF-1, B cell stimulatory factor 1; LAK, lymphokine-activated
killer; LU, lytic units.
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tumor cell lines Daudi, A375, K562, CRL 8083, and MOLT-4 were obtained from the
American Type Culture Collection, Rockville, MD. Line 7E is an EBV-transformed B cell
line (15). All cell lines were grown in continuous culture.
Culture Conditions.
￿
PBMC were cultured in RPMI 1640 medium supplemented with
10% FCS, 50 U/ml penicillin, 50,ug/ml streptomycin, 2 mM glutamine, and 5 X 10-5 M
2-ME. MLCs were established with 106 responding cells and 106 irradiated stimulating
cells. Blasts to be used as target cells forthe CTL assay were prepared by culturing freshly
isolated PBMC for 3 dwith 1% PHA (Gibco Laboratories, Grand Island, NY). Allprimary
lymphoid cells were cultured in 2-ml volumes in 24-well plastic plates (No. 3524; Costar,
Cambridge, MA) at 37°C in 10% C02.
Cell cultures to be assessed for cytolytic activity were washed twice in tissue culture
medium and diluted serially in 96-well V-bottomed plates (Costar). 2 X 106 "Cr-labeled
target cells were added to each well to a final volume of 0.2 ml/well. After 4 h of
incubation at 37°C, the plates were centrifuged and 150 Fl supernatant was removed
from each well. "Cr content of supernatants was determined by using an Auto Gamma
5780 gamma counter (Packard Instrument Co., Downers Grove, IL). 1 lytic unit (LU)
was defined as the fraction of the initial culture required to achieve 25 or 50% lysis of
the target cell population (PHA blasts and Daudi, respectively), and wasdetermined from
dose-response curves. Spontaneous release was determined by incubating target cells in
medium. Maximumrelease was determined by incubating target cellsin 1 N HCl. Percent
specific "Cr release was calculated according to the formula: 100 X [(experimental cpm)
- (spontaneous cpm)]/(maximum cpm) - (spontaneous cpm)].
Lymphokines.
￿
Human rIL-2 was cloned pursuant to an agreement between Immunex
Corp., Seattle, WA, andHoffman LaRoche, Inc., Nutley, NJ,and purified to homogeneity
as described in detail elsewhere (16). A human BSF-1 cDNA was cloned from a library
made from RNA extracted from peripheral blood T lymphocytes (purified by E rosetting)
activated for 18 h with PHA and PMA. The BSF-1 cDNA clone was isolated by
hybridization with a synthetic oligonucleotide (17). rBSF-1 was produced in yeast usinga
plasmid that directed BSF-1 expression and secretion. Recombinant protein was purified
from crude yeast supernatant by acetone precipitation and ion-exchange chromatography
on Mono S (Pharmacia Fine Chemicals, Piscataway, NJ). Mono S-purified rBSF-1 was
treated with N-glycanase (10 U, Genzyme, Boston, MA), and repurified on a ProRPC
column (Pharmacia Fine Chemicals). The rBSF-1 was eluted with a linear gradient (0-
100% acetonitrile in 0.1% TFA). The purified rBSF-1 migrated as a single band on SDS-
PAGE with a mol mass of ^-15 kD. Purified rBSF-1 had a specific activity of 10" U/mg as
measured in a human Bcell proliferation assay (18) performed as follows. Briefly, human
tonsillar B cells were purified by depletion of T cells by E rosetting followed by depletion
of granulocytes and monocytes by Sephadex G10 filtration. The resulting B cells (>95%
pure) were assayed for their proliferative response to rBSF-1 in the presence of submito-
genic concentrations of goat F(ab')2 anti-human IgM, in a 72-h assay with 105 cells
cultured in 100 Al RPMI, 10% FCS, 5 X 10-5 M 2-ME, and 50 wg/ml gentamycin.
Results
PBMC from donor VB were sensitized in MLC to irradiated cells of unrelated
donor KB. IL-2 or BSF-1 was added either at initiation or after 4 d of culture to
a final concentration of 10 ng/ml, a dose yielding optimal CTL generation in
murine MLC (10). Cytolytic activity against VB and KB PHA blasts was assessed
on day 7. The data in Fig. 1 (summarized in Table I) demonstrate that the
addition to MLC of either BSF-1 or IL-2 individually resulted in increased levels
of cytolytic activity directed against the specific target, KB, compared with
control cultures containing no exogenous lymphokines. IL-2 enhanced CTL
activity equally well when added to culture on day 0 or day 4. Interestingly, BSF-
1 augmented CTL activity quite effectively when added late, but was relatively0.0006
cx--
0.002 0.006 0.02 0.06 0.2
Culture Fraction
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TABLE I
Effects ofBSF-1 and IL-2 on the Generation ofCytolytic Populations
FIGURE 1 .
￿
Augmentation of CTL gener-
ation in primary MLC by BSF-1 and IL-2.
Cells from day 7 VB a-KB MLC, supple-
mented at theindicatedtime with 10 ng/ml
IL-2 or BSF-1, were washed and mixed at
the indicated fraction of the initial culture
with 5tCr-labeled PHA blasts from donor
KB. Aftera 4-h incubation of effectors and
target cells, supernatants were harvested
and counted in a gamma counter. Sponta-
neousrelease = 186 cpm. Maximum release
= 1,401 cpm.
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Cell cultures were established with 106 VB or KB responding cells and 106 irradiated (3,000 rad)
stimulating cells. Human rIL-2 or rBSF-1 was added at a final concentration of 10 ng/ml at the
time of culture initiation (day 0) or after 4 d. Cytolytic activity of the cultures was tested on day
seven by incubating serial dilutions of the culture contents with 2 X 105 -"Cr-labeled PHA blast
target cellsfrom KB or VB or with the same number of Dauditarget cells. KB: spontaneous release
(SR), 186cpm; maximumrelease (MR), 1,401 cpm.VB: SR, 210 cpm; MR, 1,370 cpm. Daudi: SR,
158 cpm; MR, 1,541 cpm.
Lytic units (LU) per culture. LU were calculated from the dose-response curves (see Figs. 1 and
2). Cell recoveries in MLCranged from 147 to 254% of inputresponding cell number. Recoveries
in syngeneic (VBaVB) cultures ranged from 87 to 152%.
Thelysability of target VB was established with a control KB aVB culture supplemented with IL-
2, whichexhibited>600 LU of anti-VBactivity.
ineffective when added early. In fact, when BSF-1 was present together with IL-
2 from the beginning of culture, the lytic activity that normally develops in
cultures supplemented with IL-2 alone was almost totally inhibited (Table 1).
The relative inefficiency ofBSF-1 when added either alone or with IL-2 at day
0 was notdue to a more rapid CTL response that peaked before the normal (day
7) time ofassay (data not shown).
Table 11 shows the results ofan experiment with three different blood donors.
CTL were generated in MLC in which either BSF-1 or IL-2 had been added at
day 3. In four of the six allogeneic cultures, the generation of lytic activity
against PHA blast target cells from the stimulating cell donor was significantly
enhanced (>_3-fold) by BSF-1 when compared with control cultures (GR aCL,
KZ aCL, CL aGR, GR aKZ). BSF-1 showed only marginal (twofold) effects for
Culturesupplement
Target Culture IL-2 +
Day 0: Medium IL-2 BSF-1 BSF-1
Day 4: - - IL-2 BSF-1
KB VBaKB ^-4* 100 14 18 90 50
VBaVB <1 <1 <1 <1 <1 <1
VB VBaKB <1 <1 <1 <1 <1 <1
VBaVB <1 <2 <1 <2 <1 <2
Daudi VBaKB <2 256 <2 5 56 <1
VBaVB <3 286 <1 7 77 <11450 INTERLEUKIN 4 REGULATION OF CYTOLYTIC CELL POPULATIONS
TABLE II
BSF-1 Enhances the Generation ofAllospecific CTL
Cell cultures were established with 106responding cells and 106stimulating cells. Lymphokines (10
ng/ml) were added at day 3. Cytolytic activity against "Cr-labeled PHA blasts was tested on day
seven. Results areexpressedas lytic units perculture. CL: SR, 238cpm; MR, 1,380cpm. GR: SR,
121 cpm; MR, 1,233 cpm. KZ: SR, 131 cpm; MR, 844 cpm.
* NT, Nottested.
one combination (CL aKZ), and no activity with another (KZ aGR). In all cases,
IL-2 also enhanced CTL generation.
CTL generated in MLC supplemented with either BSF-1 or IL-2 were specific,
since only minimal lytic activity was observed against target cells from the
responding cell donor (Tables I and II). Furthermore, the enhancement by IL-
2 or BSF-1 ofCTLactivity againstallogeneic targets was in most cases dependent
on the presence of an alloantigenic stimulus in the culture, since only weak
activity developed in cultures established without allogeneic stimulating cells
(Tables I and II). The single exception was the IL-2-supplemented CL aCL
culture, which exhibited lytic activity against target GR. These data demonstrate
that BSF-1 is a potent helper factor for the generation ofantigen-specific CTL,
and that the CTL generated in the presence of BSF-1 are dependent on antigen
for their induction and lytic specificity.
Additional information concerning the T cell nature of the cytolytic cells
generated in the presence ofexogenous BSF-1 was obtained in an experiment in
which MLC cells were separated on day 7 on the basis of the expression of the
CD2antigen (the cell surfacereceptorfor SRBC)before testingin the cytotoxicity
assay. ^-90% of the cells from BSF-I-supplemented MLC rosetted with SRBC;
this population contained the vast majority (96%) ofthe total lytic activity present
in the unfractionated population. Thus, the antigen-specific lytic cells that arise
in MLC in the presence ofexogenous BSF-1 are indeed CTL.
To test the effects of IL-2 and BSF-1 on the generation of cytotoxic cells in
the absence of antigen (i.e., LAK cells), the LAK-sensitive, NK cell-insensitive
tumor cell line, Daudi, was used as a target (12). Data in Fig. 2 and Table I are
in agreement with previous reports (12, 13) that IL-2 is a potent inducer ofLAK
activity. In the present experiments, strong anti-Daudi lytic activity developed
when IL-2 was used to supplement either autologous VBaVB cultures or allo-
geneic VB a-KB MLC. In contrast, no anti-Daudi activity above that generated
Culture
Medium
Target CL
IL-2 BSF-1 Medium
Target GR
IL-2 BSF-1 Medium
Target KZ
IL-2 BSF-1
KZ aCL ^-5 56 58 NT* NT NT <2 <2 <2
KZ aGR NT NT NT 7 19 ^-5 <2 <2 <2
KZ aKZ <2 <2 <2 <2 <4 <2 NT NT NT
GR aCL 29 91 167 <2 <2 <2 NT NT NT
GR aGR <3 <4 <2 NT NT NT <2 <2 <2
GR aKZ NT NT NT <2 <2 <2 <4 37 128
CL aCL NT NT NT ^-4 67 <2 <2 <4 <2
CL aGR <2 <3 <2 15 77 45 NT NT NT
CL aKZ <2 <4 <2 NT NT NT 43 139 91100
d
c 80 W
d
60
Culture Supplement
*IL2d.0
o BSF-1 d.0
" BSF-1 d.4
n Medium
Culture Froction
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TABLE III
Cytolysis ofVarious Cultured Target Cell Lines by Lymphocytes
Cultured in IL-2 or BSF-1
Fresh PBL were cultured for 7 d and then tested for lytic activity against
the indicatedcell lines. Results representpercent specific "Crrelease from
the indicated cell line by one-eighth of the contents of cultures supple-
mented with the indicated lymphokine. Spontaneous and maximum re-
lease from targets was as follows: Daudi, SR 125, MR 1350; A375, SR
1055, MR 10291; K562, SR 177, MR 3133; 7E, SR 313, MR 3404; CRL
8083, SR 164, MR 1783; MOLT 4, SR 127, MR 723.
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FIGURE 2.
￿
LAKactivity is induced by IL-
2 but not BSF-1. Cells from cultures estab-
lished with 106 VB and 106 autologous, ir-
radiated VB cells were tested on day 7 for
cytolytic activity against "Cr-labeled Daudi
target cells. Cultures were supplemented at
10 ng/ml with lymphokines at the indicated
time. Spontaneous release = 158 cpm, max-
imum release = 1,541 cpm.
in unsupplemented negative control cultures was detected in replicate cultures
containing BSF-1. Thus, despite its potent helper activity for the generation of
antigen-specific CTL, BSF-1 failed to induce LAK cells from the same donor
(Table I) or in other experimentsinvolving fouradditional donors. Furthermore,
as observed for the generation of CTL, the development of LAK activity that
normally occurs in cultures supplemented with IL-2 was inhibited when BSF-1
was present at culture initiation along with IL-2. The absence ofLAK activity at
day 7 in BSF-1-supplemented cultures was not due to an earlier appearance (and
subsequent disappearance) of LAK cells (data not shown).
Six different continuous culture cell lines have been used as targets for killer
cells generated in response to lymphokine in the absence of antigen (Table III).
Whereas all six targets were lysed by cells cultured in IL-2, in no instance did
lytic activity in BSF-1-supplemented cultures differ significantly from activity
arising in cultures supplemented only with medium.
Table IV, Exp. 1, showsresultsofadose-responseexperiment in which cultures
supplemented with various amounts ofIL-2 or BSF-I were tested for anti-Daudi
lytic activity. At concentrations of 1 ng/ml IL-2 and higher, LAK cells were
readily demonstrable; however, no LAK activity was seen in replicate cultures
supplemented with BSF-1, even atthe highest tested concentration of100 ng/ml.
Target Medium IL-2 BSF-1
Daudi 7 63 7
A375 1 64 0
K562 20 73 23
7E 2 16 1
CRL 8083 0 12 1
MOLT-4 27 75 20145 2 INTERLEUKIN 4 REGULATION OF CYTOLYTIC CELL POPULATIONS
TABLE IV
Dose-response ofIL-2 and BSF-1 in CTL and LAK Generation
* 106cells ofdonorGR were incubated for 7 d with the indicated dose of
IL-2 or BSF-1. Lyticactivity against "Cr-labeled Daudi target cells was
tested on day 7.
$106 cellsof donor KZ were incubated in MLCwith 106irradiated (3,000
rad) cells from donor CL. Lymphokines were added to the cultures on
day 4 and cytolytic activity against PHA blasts from donor CL was
measured on day 7.
§LU per culture, determined from dose-response curves as in legend to
Fig. 1.
NT, Not tested.
Thus, IL-2 is at least 1,000-fold more potent than BSF-1 at inducing LAK cells
from human peripheral blood. This is in contrast to the effects of BSF-1 and IL-
2 on antigen-specific CTL generation, where either lymphokine augmented
activity at concentrations in excess of 1 ng/ml (Table IV, Exp. 2).
Discussion
The results presented here demonstrate that BSF-1 can exhibit both positive
and negative regulatory effects on the in vitro generation of human antigen-
specific CTL, depending on the time of its addition to culture. However, BSF-1
failed to induce any demonstrable lytic activity in the absence of an antigenic
stimulus (LAK cells) and, furthermore, inhibited the IL-2-induced generation of
both CTL and LAK cells when added at culture initiation.
BSF-1 enhanced CTL generation when added to MLC after a 3-4 d activation
period, but was less effective when added at culture initiation. Despite its ability
to amplify the generation of antigen-specific CTL, BSF-1, even when added late
to cultures containing no antigenic stimulus, induced little or no LAK activity as
defined by lysis of the Daudi cell line or any of five other continuous culture
target cell lines. IL-2, on the other hand, showed CTL helper activity and
induced LAK cells when added to culture at either time. Since these results do
not reflect a difference in the kinetics of appearance of lytic cells in cultures
containing exogenous IL-2 or BSF-1, they may indicate that the two lymphokines
exert their effects on different cellular subsets and, perhaps, at different stages
of cellular activation.
When both BSF-1 and IL-2 were present together from the beginning of
culture, the generation of CTL and LAK was severely depressed compared to
the activity that developed in cultures containing IL-2 but no exogenous BSF-1 .
It is possible that the precursors of the cytolytic or Th cells involved in the CTL
Lymphokine
concentration
Exp.
IL-2
1: LAK*
BSF-1
Exp. 2:
IL-2
CTL$
BSF-I
ng/ml
300 NT11 NT 83 43
100 160 <1 67 33
10 104 <1 30 63
1 33 <1 8 9
0.1 <2 <1 NT 5
0 <1 5 5WIDMER ET AL.
￿
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or LAK response become refractory to signals normally provided by IL-2 if they
have been exposed early to BSF-1. Alternatively, BSF-1 may induce the devel-
opment of a separate population ofcells that suppresses CTL and LAK genera-
tion. Experiments are in progress to examine further the underlying mechanism
of this phenomenon.
The cytolytic cells stimulated in MLC containing exogenous BSF-1 bear the
CD2 T cell marker, require an antigenic stimulus for induction, and exhibit
antigen-specific lytic activity in a short-term assay; thus, they display both cell-
surface and functional properties of T cells. We have not further investigated
the cellular requirements for BSF-1-induced CTL amplification. However, in
murine MLC, BSF-1 stimulates CTL generation from purified CD8' CTL
precursors in the absence of other T cells (10). Furthermore, BSF-1 stimulates
proliferation of both activated CD8+ (10, 19, 20) and CD4+ (19, 20) subpopula-
tions, as well as cloned CTL (19) and Th cells (19, 21). Thus, it is evident that
BSF-1 affects CTL generation, at least in part, through its direct action on cells
of the CTL lineage. However, BSF-1 may also exert some of its effects via an
intermediary helper cell. In this regard, it is important to note that BSF-1-
induced T cell proliferation is not affected by antibodies against IL-2 or its
receptor (20, 21). Furthermore, BSF-1 failed to induce IL-2 mRNA in BSF-1-
responsive Tcell clones and populations (our unpublished observation).
These findings concerning the functional relationships of IL-2 and BSF-1 in
terms of CTL and LAK generation have important implications for the use of
these lymphokines to expand lymphoid cells for immunotherapy of cancer (22).
In some in vivo model systems (23, 24), CTL orLyt-2+populationsare important
in tumor elimination. Based on the in vitro results presented here, it is tempting
to speculate that BSF-1, either alone or in combination with IL-2, may be useful
for generating immunotherapeutic cellular populations enriched for antigen-
specific CTL. It will thus be important to determine whether BSF-1 has effects
on the generation of tumor-specific CTL similar to those described here in an
allogeneic model system.
Summary
The effects of B cell stimulatory factor 1 (BSF-1) on the generation of human
CTL and lymphokine-activated killer (LAK) cells in vitro were investigated. Both
L-2 and BSF-1 were potent helper factors for the generation ofantigen-specific
CTL in MLC; detection of optimal BSF-1-induced CTL activity in this system
occurred when BSF-1 was added to cultures after an initial period of activation
during which exogenous BSF-1 was not present. In contrast to IL-2, BSF-1 failed
to induce an LAK cell population, as detected with Daudi tumor targets, in
cultures that had not been allosensitized. Furthermore, when both lymphokines
were added together at culture initiation, BSF-1 inhibited the IL-2-driven gen-
eration of cytolytic cells. The differential ability of BSF-1 to promote the
generation of CTL but not LAK could have important implications for lympho-
kine-mediated immunotherapy.
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